Home Newsfeeds Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023

byBenzinga Newsdesk

January 25, 2023

1 minute read

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy

Bolsters Presence in Neuroscience

Expected to be Accretive in 2023

Rio Tinto To Acquire Chilean Exploration Assets And Enter Joint Venture With Codelco; Will Acquire PanAmerican Silver’s 57.74% Operating Stake In Agua De La Falda For $45M, 100% Meridian Property for $550K And The Grant Of New Smelter Returns Royalties

By Happy Mohamed

July 31, 3:50 PM

Rio Tinto has agreed to purchase PanAmerican Silver’s stake in Agua de la Falda S.A. (“Agua de la Falda”), a company with exploration tenements in Chile’s prospective Atacama region, and to enter

PAAS

Why Are Phio Pharmaceuticals Shares Trading Higher Today

By Vandana Singh

May 16, 12:14 PM

Phio Pharmaceuticals Corp (NASDAQ: PHIO) shares are gaining after the FDA cleared its Investigational New Drug (IND) application to proceed with a clinical trial of Phio's

PHIO

Catalent’s Activist Board Presence To Boost Operational Recovery, Analyst Says

By Vandana Singh

August 30, 1:27 PM

Tuesday, Catalent Inc (NYSE: CTLT) reported Q4 adjusted EPS of $0.09, missing the consensus of $0.10, with sales of $1.07 billion, down 17% Y/Y, slightly above the

CTLT

‘FDA Advisors Weigh Whether Alzheimer’s Drug Leqembi Should Receive Full Approval, Will Make A Final Decision On July 6’ – CNBC

By Happy Mohamed

June 9, 11:10 AM

https://www.cnbc.com/2023/06/09/fda-advisors-review-alzheimers-drug-leqembi-for-full-approval.html The FDA’s independent advisors will make a recommendation on whether Eisai and Biogen’s Alzheimer’s

BIIB

Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Related Posts

Rio Tinto To Acquire Chilean Exploration Assets And Enter Joint Venture With Codelco; Will Acquire PanAmerican Silver’s 57.74% Operating Stake In Agua De La Falda For $45M, 100% Meridian Property for $550K And The Grant Of New Smelter Returns Royalties

Why Are Phio Pharmaceuticals Shares Trading Higher Today

Catalent’s Activist Board Presence To Boost Operational Recovery, Analyst Says

‘FDA Advisors Weigh Whether Alzheimer’s Drug Leqembi Should Receive Full Approval, Will Make A Final Decision On July 6’ – CNBC